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Darbepoetin alfa:  An Effective Treatment with Flexible
and Simplified Dosing for Anemia in Patients with Cancer
James G. Stevenson, Pharm.D., and James J. Natale, Pharm.D.
Anemia is common in patients with cancer or myelodysplastic syndrome.
Erythropoietic therapy offers an effective way to manage anemia by increasing
hemoglobin levels, decreasing transfusion requirements, and alleviating
symptoms.  We reviewed data showing the feasibility and effectiveness of
treatment with the erythropoiesis-stimulating protein darbepoetin alfa at
extended dosing intervals to treat anemia in patients with cancer receiving
multicycle chemotherapy.  We also explored the darbepoetin alfa’s potential
for treating anemia in patients with myelodysplastic syndrome.  Data from
clinical studies and drug therapy evaluations confirm that darbepoetin alfa
administered weekly, every 2 weeks, and every 3 weeks corrects and maintains
hemoglobin levels in patients with chemotherapy-induced anemia.  In
addition, the data demonstrate that both weight-based and fixed dosing with
darbepoetin alfa are effective, and that early intervention to treat anemia has
clinical benefits.  Darbepoetin alfa also is an effective treatment for anemia in
patients with cancer not receiving chemotherapy, at extended dosing intervals
of at least 3 weeks.  Extended dosing for anemia treatment can provide
benefits for patients, caregivers, and clinicians because it reduces the number
of clinic visits needed and permits synchronizing anemia treatment with
chemotherapy cycles.  Data from recent studies suggest that darbepoetin alfa
is effective for treating anemia in patients with myelodysplastic syndrome; this
potential use is being investigated further in ongoing studies.  Thus,
darbepoetin alfa is an attractive therapy option for patients with chemotherapy-
or cancer-induced anemia.  It allows increased flexibility and simplified
dosing and may offer some benefit in the treatment of anemia in patients with
myelodysplastic syndrome.
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Anemia in patients with cancer can be treated
effectively with erythropoiesis-stimulating
proteins, such as recombinant human
erythropoietin (rHuEPO; epoetin alfa and epoetin
beta) and darbepoetin alfa.  However, despite the
treatment benefits, anemia in this patient
population remains an undertreated condition.1, 2
The symptoms of anemia, including fatigue,
lethargy, reduced functional and cognitive
capacity, and weakness, all have a considerable
impact on health-related quality of life.3–7 In
addition to these negative effects, fatigue, in
particular, may result in additional loss of work
productivity in patients with cancer.8 Thus,
effective treatment of anemia in this patient
population is important from several perspectives.
Both rHuEPO and darbepoetin alfa stimulate
erythropoiesis by the same mechanism as
endogenous erythropoietin.  By binding to the
erythropoietin receptor,9 these agents effectively
increase and maintain hemoglobin levels and
reduce the need for transfusions.  Recombinant
human erythropoietin has a relatively short half-
life (4–8 hrs).  For treatment of anemia in
patients with cancer receiving concomitant
chemotherapy, the starting dosage of epoetin alfa
approved by the United States Food and Drug
Administration (FDA) is 150 units/kg 3
times/week or 40,000 units/week.10 However,
darbepoetin alfa has two additional carbohydrate
chains, resulting in an extended half-life
compared with rHuEPO, which creates the
potential for less frequent dosing.9, 11 The initial
FDA-approved dosage of darbepoetin alfa for
patients with chemotherapy-induced anemia was
2.25 µg/kg/week,12, 13 and recently, 500 µg every 3
weeks was approved.13
Patients, their caregivers, and clinicians could
benefit from anemia treatment administered less
frequently.  Clinic visits can be a considerable
burden for patients and caregivers in terms of
time, impact on daily life, and cost,14–16 so
reducing the number of visits would be
beneficial.  A survey of patients with cancer
receiving anemia treatment found that
approximately 2 hours for patients and 1 hour
for their caregivers was required for each visit.15
Visits to the clinic for anemia treatment can
adversely affect patients and caregivers in many
ways, such as taking time off from work,
changing or canceling social functions or
vacations, and failing to accomplish household
responsibilities.14, 15 For patients experiencing
anemia-related fatigue, clinic visits may further
deplete already low energy reserves.14 Also, visits
may involve out-of-pocket expenses for patients
and their accompanying caregivers.16
Less frequent dosing could also reduce the time
clinicians spend preparing and administering
injections, thereby increasing the efficiency of
their clinics through better use of resources.
Time-and-motion data confirm that when long-
acting growth factors are administered to treat
cancer-associated anemia and neutropenia, fewer
clinic visits result in significant time savings for
clinic staff.17 Because many chemotherapy
regimens are administered in 3-week cycles
(Figure 1),18 less frequent administration of
anemia treatment could be synchronized with the
chemotherapy cycles.
The benefits of darbepoetin alfa in the
management of cancer- and chemotherapy-
related anemia have become clearer with
additional data from clinical trials and increased
clinical experience.
Etiology of Anemia in Patients with Cancer or
Myelodysplastic Syndrome
Anemia, a common complication among
patients with cancer (Figure 2),18, 19 may occur as
a result of cancer treatment, or as a direct or
indirect effect of the malignancy itself.20, 21
Chemotherapy is a frequent cause of anemia
through a range of mechanisms, including stem
cell death, blockage of hematopoietic factors, and
damage to mature hematopoietic cells.20 Patients
may also develop anemia even if they are not
receiving chemotherapy. Other causes of anemia
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Figure 1. Distribution of patients receiving chemotherapy
in the United States during 2000 by cycle length.  Most
chemotherapy regimens were estimated to be administered
in 3–4-week cycles.  (From reference 18 with permission.)
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in patients with cancer are chronic blood loss,
hemolysis, and displacement of bone marrow due
to invasion by the tumor.20, 21 Another cause may
be the release of cytokines such as interferons,
interleukin-1, and tumor necrosis factor-a by the
immune and inflammatory system in response to
the malignancy.22, 23 Increased levels of these
cytokines can produce effects that contribute to
the development of chronic anemia of cancer,
such as reduced life span of red blood cells,
inadequate erythropoietin production or
utilization, and impaired iron utilization.22
Myelodysplastic syndrome is a neoplastic
clonal stem cell disorder characterized by bone
marrow failure and a tendency to progress to
acute myelogenous leukemia.24 Cytopenia,
particularly anemia, is the most common clinical
manifestation, and myelodysplastic syndrome is a
frequent cause of anemia in the elderly.  Anemia
in patients with myelodysplastic syndrome
results from ineffective hematopoiesis, thought to
be caused by increased intramedullary apoptosis,
although the exact contributing mechanisms
remain unknown.25
Guidelines for Erythropoietic Treatment in
Patients with Cancer
Given the impact of anemia in patients with
cancer, treatment guidelines concerning
erythropoietic therapy in this population have
been established, such as those from the
American Society of Clinical Oncology–American
Society of Hematology.26 These guidelines
recommend erythropoietic treatment for patients
with chemotherapy-associated anemia and
hemoglobin levels of 10 g/dl or less.  For patients
with hemoglobin levels of greater than 10 g/dl
but less than 12 g/dl, these guidelines
recommend that deciding whether to administer
epoetin alfa is based on the patient’s clinical
manifestation of anemia.
Similarly, the European Organization for
Research and Treatment of Cancer recommends
erythropoietic therapy for patients whose
hemoglobin level is 9–10 g/dl.27 Therapy should
be based on anemia-related symptoms both in
patients with cancer receiving chemotherapy
and/or radiotherapy and in those not receiving
these treatments.  The National Comprehensive
Cancer Network’s evidence-based practice
guidelines for treating cancer- and treatment-
related anemia recommend considering appro-
priate treatment after a patient’s hemoglobin level
decreases to 11 g/dl or less.28
Regardless of which recommendations are used
on when to start erythropoietic therapy, all of
these guidelines support a similar target
hemoglobin concentration.  The American
Society of Clinical Oncology–American Society of
Hematology and the National Comprehensive
Cancer Network recommend a target hemoglobin
concentration of 12 g/dl, and the European
Organization for Research and Treatment of
Cancer recommends maintaining a concentration
of 12–13 g/dl.
Darbepoetin alfa
Chemotherapy-Induced Anemia
Establishing the Efficacy of Darbepoetin alfa
Once/Week and Every 2 Weeks
A 2002 active-controlled study involving
patients receiving multicycle chemotherapy and
subcutaneous darbepoetin alfa 0.5–8.0 µg/kg/
week for 12 weeks demonstrated that weekly
administration raised hemoglobin levels.29 Mean
change in hemoglobin level was 1.4 g/dl in the
0.5-µg/kg/week cohort and 2.75 g/dl in the 8.0-
µg/kg/week cohort.  A dose-response relationship
was apparent with doses up to 4.5 µg/kg.  Based
on this study’s findings, the minimum effective
dose with respect to reducing blood transfusions
was 1.5 µg/kg/week.12
The efficacy of a weekly regimen was confirmed
in a large, double-blind, placebo-controlled phase
III study of 320 patients receiving chemotherapy
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Figure 2. Distribution of patients with cancer-related
anemia in the United States during 2000 by the most
common types of cancer associated with chemotherapy- and
cancer-related anemia.  NHL = non-Hodgkin’s lymphoma.
(From reference 18 with permission.)
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for lung cancer.30 Significantly fewer patients
receiving darbepoetin alfa 2.25 µg/kg/week than
those receiving placebo required red blood cell
transfusions from week 5 to the end of the
treatment phase (27% [95% confidence interval
(CI) 20–35%] vs 52% [95% CI 44–66%],
p<0.001).  Furthermore, a greater proportion of
patients in the darbepoetin alfa group had a
hematopoietic response (defined as an increase in
hemoglobin level of at least 2 g/dl, or achieving a
hemoglobin level of at least 12 g/dl in the
absence of a red blood cell transfusion in the
previous 28 days).  Hematopoietic response in
the darbepoetin alfa and placebo groups was 66%
(95% CI 58–74%) and 24% (95% CI 16–31%),
respectively (p<0.001).
Early dose-finding data also provided the first
evidence that extending the frequency of
darbepoetin alfa administration from every week
to every 2 weeks does not reduce efficacy.29
Across a range of doses, the proportion of
patients with a hematopoietic response was
similar when twice the weekly dose was
administered once every 2 weeks.  Results from a
multicenter, open-label, noncomparative study
confirmed that darbepoetin alfa can alleviate
chemotherapy-induced anemia when given every
2 weeks.31, 32 Over the 16-week study period,
patients with nonmyeloid malignancies and
anemia (baseline hemoglobin level ≤ 11 g/dl)
receiving multicycle chemotherapy were given
eight doses of subcutaneous darbepoetin alfa 3.0
µg/kg every 2 weeks.  Interim results showed a
rapid and steady increase in hemoglobin level
(Figure 3).
Final data were presented for all 1558 patients
enrolled in the study.  Mean change in hemo-
globin level was 1.7 g/dl (95% CI 1.6–1.8).  Over
70% of patients achieved a hematopoietic
response (increase in hemoglobin level ≥ 2 g/dl
or achieving a hemoglobin level ≥ 12 g/dl in the
absence of a red blood cell transfusion in the
previous 28 days).  Overall, 19% (95% CI
17–21%) of patients required a red blood cell
transfusion.32 The results of this study, with
darbepoetin alfa administered every 2 weeks, are
similar to those seen with commonly used
rHuEPO dosing regimens, such as 10,000 units 3
times/week or 40,000 units once/week, in large
community-based studies of epoetin alfa.31, 33–35
Potential for Fixed Dosing
Recent studies have demonstrated that
darbepoetin alfa administered using fixed rather
than weight-based dosing may simplify anemia
management.36–39 A drug use evaluation,
conducted by the US Oncology Network,
suggested that a fixed dose of darbepoetin alfa
200 µg every 2 weeks is effective in treating
chemotherapy-induced anemia in patients naïve
to erythropoietic therapy, and in maintaining
hemoglobin levels in patients previously
stabilized with epoetin alfa.36 Additional
retrospective cohort studies confirmed that a
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Figure 3. Mean hemoglobin concentrations (with 95%
confidence intervals) in patients with cancer receiving
chemotherapy who were given eight doses of subcutaneous
darbepoetin alfa 3.0 µg/kg every 2 weeks.  (From reference
31 with permission.)
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Table 1.  Summary of Retrospective Cohort Studies of Darbepoetin alfa in Clinical Practice
Darbepoetin alfa Epoetin alfa
Most Common Initial Dosage Percentage of Patients Most Common Initial Dosage Percentage of Patients
No. of (% of patients receiving Who Required (% of patients receiving Who Required
Patients this dosage) Dosage Increasea this dosage) Dosage Increasea
139137 200 µg every 2 wks (75.2) 11.4 40,000 units/wk (74.2) 14.0
278538 200 µg every 2 wks (61.0) 22.0 40,000 units/wk (72.0) 23.0
40839 100 µg/wk (49.0) 16.0 40,000 units/wk (86.0) 24.0
aThese patients refer to those who had received the most common initial dosage.
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fixed dose of darbepoetin alfa 200 µg every 2
weeks is effective in treating anemia in patients
receiving chemotherapy.37–39 The rates of dose
escalation in these studies were comparable to
rates seen with epoetin alfa (Table 1).
Comparison of Darbepoetin alfa Every 2 Weeks
with Epoetin alfa Once/Week
Several head-to-head comparison studies
assessed the relative efficacy of darbepoetin alfa
every 2 weeks and epoetin alfa once/week.  In
one study, patients with anemia who had breast,
lung, or gynecologic cancer and were receiving
multicycle chemotherapy were randomized to
receive darbepoetin alfa 200 µg every 2 weeks or
epoetin alfa 40,000 units/week for up to 16
weeks.40 Doses were increased (frequencies
remained the same) to darbepoetin alfa 300 µg
and epoetin alfa 60,000 units after 4 weeks if
hemoglobin levels had increased less than 1 g/dl
from baseline.
In a combined analysis incorporating these
three tumor types and a total of 312 patients, the
rate of red blood cell transfusions over the
treatment period was similar in both groups, with
16% and 17% in the darbepoetin alfa and epoetin
alfa groups, respectively. The hematopoietic
response at the end of treatment (the proportion
of patients whose hemoglobin increased by ≥ 2
g/dl or who achieved a hemoglobin concentration
≥ 12 g/dl) was similar, with 69% and 72% in the
darbepoetin alfa and epoetin alfa groups,
respectively.
The target hemoglobin concentration range
was 11–13 g/dl, and similar proportions of
patients in both treatment groups achieved a
hemoglobin level of at least 11 g/dl, with 82%
and 86% for the darbepoetin alfa and epoetin alfa
groups, respectively.  Of these patients, 81% and
75% maintained levels within the target range.
Thus, both treatments appeared to have com-
parable efficacy in improving and maintaining
hemoglobin concentrations as well as reducing
transfusion requirements.
Another study involved 358 patients with
anemia (hemoglobin concentration ≤ 11.0 g/dl)
who had solid tumors and were scheduled to
receive chemotherapy for at least 12 weeks.41
Patients in this study were also randomized to
receive darbepoetin alfa 200 µg every 2 weeks or
epoetin alfa 40,000 units/week for 16 weeks.
Doses were increased to darbepoetin alfa 300 µg
after 6 weeks and to epoetin alfa 60,000 units
after 4 weeks if hemoglobin levels had increased
by less than 1 g/dl.  In an analysis based on data
for the first 305 patients who completed 4 weeks
of study treatment, the proportion of patients
whose hemoglobin concentration increased by at
least 1 g/dl in the first 4 weeks of treatment was
32.5% and 47.0% for those receiving darbepoetin
alfa and epoetin alfa, respectively (p=0.0078).
(Levels obtained within 28 days of a transfusion
were excluded from this analysis.)
For 318 study patients at risk of needing a
transfusion from week 5 to the end of the study,
transfusions were required in 17.8% and 12.9%
in the darbepoetin alfa and epoetin alfa groups,
respectively (p=0.2936).  The proportion of
patients whose hemoglobin levels increased by at
least 2 g/dl by the end of the study was 41.8%
and 57.7% in the respective groups (p=0.004).
These results differ from those of previous and
subsequent studies of these two treatments;
however, this may reflect different dosage
escalation and reduction used for each treatment
during the study. Hematopoietic response rates
were not evaluated.
A larger study involved 1220 patients with
nonmyeloid malignancies who were scheduled to
receive at least 8 weeks of chemotherapy.42
Again, patients were randomized to receive
darbepoetin alfa 200 µg every 2 weeks or epoetin
alfa 40,000 units/week for up to 16 weeks.  A
total of 1209 patients received at least one dose
of study drug and were included in the primary
analysis data set.  From week 5 to the end of
treatment, 21% (95% CI 17–24%) of patients
receiving darbepoetin alfa also received a red
blood cell transfusion, compared with 16% (95%
CI 12–19%) of those receiving epoetin alfa.  The
upper limit of the 95% CI of the difference
between groups was 10.8%, which is below the
prespecified noninferiority margin of 11.5%.
Thus, noninferiority regarding transfusion was
demonstrated with darbepoetin alfa 200 µg every
2 weeks compared with epoetin alfa 40,000
units/week.  A similar proportion of patients in
both treatment groups achieved the target
hemoglobin concentration range (11–13 g/dl),
with 80% and 86% in the darbepoetin alfa and
epoetin alfa groups, respectively.
In a recent review of darbepoetin alfa (1087
patients) versus epoetin alfa (1415 patients),
analysis of trials did not show a significant
difference between the two treatments in
hemoglobin response, transfusion reduction, or
thromboembolic events.43 In addition, compar-
ative analysis produced no conclusions about
quality of life, tumor response and progression,
438
DARBEPOETIN ALFA FOR ANEMIA IN PATIENTS WITH CANCER  Stevenson and Natale
survival, or adverse outcomes other than
thromboembolic events.
Extended Dosing Intervals
A two-part, randomized, double-blind, dose-
finding study investigated the efficacy of
administering darbepoetin alfa every 3 weeks in
249 patients with anemia (hemoglobin level ≤
11.0 g/dl) who had cancer and were receiving
multicycle chemotherapy.44 In part A of the
study, patients were randomized in a 4:1 ratio to
receive up to 12 weeks of placebo or subcu-
taneous darbepoetin alfa at one of six doses
ranging from 4.5–15.0 µg/kg every 3 weeks.  In
part B, patients who completed part A and
continued receiving chemotherapy could choose
whether to continue receiving open-label
darbepoetin alfa every 3 weeks for up to 12 more
weeks.
Hematopoietic response rates ranged from 51%
(95% CI 33–70%) in the darbepoetin alfa 4.5-
µg/kg group to 71% (95% CI 52–91%) in the 12-
µg/kg group.  No further increase was seen in the
proportion of patients achieving a hematopoietic
response with darbepoetin alfa doses greater than
12 µg/kg every 3 weeks.  Fewer patients in the
darbepoetin alfa groups than in the placebo
group required red blood cell transfusions from
week 5 to the end of the treatment phase.
Transfusion rates in the darbepoetin alfa groups
ranged from 19% (95% CI 6–32%) to 30% (95%
CI 16–44%) compared with 46% (95% CI
32–61%) in the placebo group.  No significant
differences in transfusion rates were observed
between the darbepoetin alfa groups.
In another randomized trial, 81 patients with
anemia (hemoglobin levels 9–11 g/dl) who had
cancer and were receiving chemotherapy every 3
weeks were randomized to receive darbepoetin
alfa 6.75 µg/kg every 3 weeks either 1 week
before each chemotherapy cycle (asynchronous)
or on the same day as chemotherapy (synchro-
nous) for up to 16 weeks.45 With either schedule,
darbepoetin alfa administered once/chemotherapy
cycle was effective in treating chemotherapy-
induced anemia.  After 6 weeks of therapy, the
mean increase in hemoglobin concentration was
1.0 g/dl (95% CI 0.6–1.3) with asynchronous
darbepoetin alfa administration (43 patients) and
1.0 g/dl (95% CI 0.6–1.5) with synchronous
administration (38 patients).
As with the every-2-week darbepoetin alfa
regimen, the every-3-week schedule also may be
further simplified with fixed dosing.  Results
from a randomized clinical study indicated that a
fixed dose of 300 µg every 3 weeks is effective in
treating both mild and moderate chemotherapy-
induced anemia.46 Other recent studies have also
demonstrated that fixed dosing of darbepoetin
alfa every 3 weeks in patients with chemotherapy-
induced anemia is effective for achieving and
maintaining hemoglobin at a level consistent
with the evidence-based guidelines.47–49
One analysis involved data for 1493 patients
with chemotherapy-induced anemia (hemoglobin
< 11 g/dl) who had completed 16 weeks of
treatment with darbepoetin alfa 300 µg every 3
weeks.47 After 6 weeks, this could be increased
to 500 µg every 3 weeks if the hemoglobin level
remained below 10 g/dl and the increase from
baseline was less than 1 g/dl.  Most patients (79%
[95% CI 77–81%]) achieved and maintained the
target hemoglobin concentration of 11 g/dl or
greater.  When results were stratified by baseline
hemoglobin concentration, a greater proportion
of patients with a baseline concentration of at
least 10 g/dl versus less than 10 g/dl achieved the
target hemoglobin concentration (87% [95% CI
85–90%] vs 66% [95% CI 61–70%]).  However,
similar proportions of patients in both groups
(73% and 71%, respectively) then maintained
levels of 11–13 g/dl.
A subset analysis of patients in the study who
had breast cancer confirmed that darbepoetin alfa
every 3 weeks increased and maintained
hemoglobin concentrations of 11–13 g/dl in this
patient population.50 Again, similar proportions
of patients with baseline hemoglobin levels 10
g/dl or greater and less than 10 g/dl maintained
levels within the target range (92% [95% CI
88–95%] and 80% [95% CI 71–89%], respectively).
In another large study, 705 patients with
anemia (hemoglobin < 11 g/dl) who had non-
myeloid malignancies and were receiving chemo-
therapy were randomized to receive darbepoetin
alfa 500 µg every 3 weeks or 2.25 µg/kg once/week
for 15 weeks.48 The proportion of patients
achieving the target hemoglobin concentration of
at least 11 g/dl was similar in both groups (84%
[95% CI 81–88%] and 77% [95% CI 72–81%],
respectively, adjusted Kaplan-Meier proportions).
The rate of blood transfusions from week 5 to the
end of the treatment phase was also similar in
both groups.  Of those receiving darbepoetin alfa
every 3 weeks, 23% (95% CI 19–28%) required a
transfusion, compared with 30% (95% CI
25–30%) of the weekly treatment group
(unadjusted Kaplan-Meier estimates).  Because
the upper limit of the 95% CI for the between-
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group difference was below the prespecified
noninferiority margin of 12.5%, the every-3-week
treatment was considered comparable to weekly
treatment with respect to transfusion rate.
An exploratory analysis of data from this study
investigated the effect of reduced or withheld
doses of darbepoetin alfa on hemoglobin levels.51
Results confirmed that the starting dosage of
darbepoetin alfa 500 µg every 3 weeks, with dose
reductions of 25–50% as required, effectively
maintained hemoglobin concentrations in the
study population.  A similar proportion of
patients in the every-3-week and weekly
treatment groups required a dose reduction (74%
[95% CI 69–80%] and 75% [95% CI 70–80%],
respectively), primarily because their hemoglobin
levels increased by 1 g/dl or greater in a 2-week
period.  The average weekly doses over the entire
study period were 129.6 and 113.0 µg for the
every-3-week and weekly treatment groups,
respectively.  The safety profiles of both
treatments were similar, with no increase in
cardiovascular or thromboembolic events
associated with rapid increases in hemoglobin
concentrations.
The effectiveness of darbepoetin alfa every 3
weeks for treating chemotherapy-induced anemia
was confirmed by a recent placebo-controlled
study involving patients with nonmyeloid
malignancies.49 In this study, 386 patients with
anemia (hemoglobin < 11 g/dl) receiving
chemotherapy were randomized to receive
darbepoetin alfa 300 µg or placebo every 3
weeks.  Dose-adjustment rules during the study
allowed for an increase to darbepoetin alfa 500
µg every 3 weeks or a decrease in dose depending
on hemoglobin concentration.  In the darbepoetin
alfa group, 24% of patients received a dose
increase, and the average weekly dose was 94.6
µg every 3 weeks.
The proportion of patients achieving the
hemoglobin concentration target range of 11–13
g/dl from week 5 to the end of the treatment
period was significantly higher in the group
receiving darbepoetin alfa every 3 weeks versus
placebo (82% [95% CI 76–88%] vs 48% [95% CI
41–56%], p<0.001).  The rate of blood transfusions
during the treatment period was also significantly
lower with darbepoetin alfa versus placebo (24%
[95% CI 18–30%] vs 41% [95% CI 34–49%],
p<0.001).
Benefits of Early Intervention
There has been considerable debate as to when
anemia treatment should be started in patients
with cancer receiving chemotherapy, and few
studies have addressed this issue.  However, a
recent systematic review of trials of erythro-
poietic therapy in patients with chemotherapy-
induced anemia suggested a clinical benefit from
early intervention.52 The benefit was seen when
hemoglobin concentrations were 10 g/dl or
greater, with reduced relative risk of blood
transfusion and reduced risk of a decrease in
hemoglobin concentration to less than 10 g/dl.
Thus, early intervention with erythropoietic
therapy in patients undergoing chemotherapy is
likely to reduce the risk of severe symptomatic
anemia, with its associated detrimental effects on
health status and quality of life.
Results from a trial of fixed every-3-week
dosing confirmed that treatment with darbepoetin
alfa in patients with mild anemia can help
prevent progression of the anemia to more severe
levels.46 Patients with chemotherapy-induced
anemia and baseline hemoglobin levels of
10.5–12 g/dl were  randomized in a 1:1 ratio to
early intervention with darbepoetin alfa
(immediate therapy) or late intervention (not
treated until hemoglobin concentration dropped
to ≤ 10 g/dl).  In both groups, a fixed dose of 300
µg every 3 weeks was given for up to 23 weeks.
Data through week 17 for 201 evaluable
patients were reported.  In the early intervention
group, 29% (95% CI 19–38%) of patients
progressed to moderate anemia (hemoglobin <
10 g/dl), compared with 65% (95% CI 55–75%)
in the late intervention group (p<0.0001).  The
early intervention group maintained an average
hemoglobin level in the target range of 11–12
g/dl.  The late intervention group required
darbepoetin alfa after a median of 4.5 weeks (95%
CI 3–6) to increase hemoglobin concentrations.
Anemia of Cancer
A multicenter, dose- and schedule-finding,
open-label study in patients with nonmyeloid
malignancies who were not receiving chemotherapy
was conducted to determine the efficacy of
darbepoetin alfa in this population.53 Initially,
102 patients received subcutaneous darbepoetin
alfa for 12 weeks at escalating doses of 0.5, 1.0,
2.25, or 4.5 µg/kg/week.  Results demonstrated a
significant increase in hemoglobin concentration;
at least 70% (95% CI 53–88%) of patients with
chronic anemia of cancer in each dose cohort
achieved a hematopoietic response.
After completion of the once-weekly schedule,
different patient cohorts were enrolled in double-
blind, placebo-controlled studies of darbepoetin
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alfa every 3 weeks and every 4 weeks.  Eighty-six
patients were randomized in a 3:1 ratio to receive
treatment for 12 weeks with subcutaneous
darbepoetin alfa 6.75 µg/kg every 3 weeks, 6.75
µg/kg every 4 weeks, or 10 µg/kg every 4 weeks,
or placebo every 3 or 4 weeks.  This treatment
period was followed by an optional 12-week,
open-label, darbepoetin alfa treatment phase.  In
this phase, patients in the darbepoetin alfa group
continued to receive their study dosage, and
those who previously received placebo were
given the darbepoetin alfa dosage for which they
had previously served as the control.  A 4-week
observation period followed the last dose.
During the 12-week blinded phase, a
hematopoietic response occurred in 60% (95% CI
36–83%) and 70% (95% CI 50–91%) of patients
who received darbepoetin alfa every 3 weeks and
every 4 weeks, respectively, compared with only
10% (95% CI 0–24%) of those who received
placebo (Figure 4).  Also during this phase, the
mean increase in hemoglobin level in each cohort
receiving darbepoetin alfa was at least 1.0 g/dl,
whereas the mean concentration in the placebo
group remained unchanged.  In patients who
continued receiving darbepoetin alfa every 3 and
4 weeks in the open-label phase, hemoglobin
levels were maintained for another 12 weeks.
Overall, hemoglobin response rates were at least
comparable to those observed in similar patient
populations who received epoetin alfa 3
times/week in other studies.54, 55
Data from another multicenter study confirmed
the efficacy of darbepoetin alfa administered at
extended intervals to patients with anemia
(hemoglobin ≤ 11 g/dl) who had cancer and were
not receiving chemotherapy or radiotherapy.56
Patients were randomized in a 4:1 ratio to receive
darbepoetin alfa 3.0 µg/kg every 2 weeks for 21
weeks, or to a 12-week observation period
followed by 9 weeks of treatment with the same
dosage of darbepoetin alfa (the control group).
Data from the first 170 patients enrolled were
analyzed through the comparative phase (the
first 12 wks) of the study.  Mean baseline
hemoglobin level was 10.2 g/dl in the
darbepoetin alfa group and 10.3 g/dl in the
control group.  Mean change from baseline in
hemoglobin level was 2.1 g/dl (95% CI 1.8–2.4)
in the darbepoetin alfa group compared with the
much smaller change in the control group of 0.3
g/dl (95% CI 0.0–0.6).  A hematopoietic response
(increase of ≥ 2 g/dl in hemoglobin level and/or
achieving a hemoglobin level of ≥ 12 g/dl) was
seen in 81% (95% CI 72–91%) of patients in the
darbepoetin alfa group compared with 27% (95%
CI 10–44%) of controls.
These studies demonstrate the ability of
darbepoetin alfa administered at extended dosing
frequencies to increase and maintain the
hemoglobin concentrations of patients with
chronic anemia of cancer.
Myelodysplastic Syndrome
Given the proven effectiveness of darbepoetin
alfa in treating cancer- and chemotherapy-related
anemia, its potential in the management of
anemia in patients with myelodysplastic
syndrome also is being explored.  Numerous
studies have been performed in patients with
low- and intermediate-risk myelodysplastic
syndrome.57–63
In one study, patients with anemia who had
myelodysplastic syndrome (hemoglobin level ≤
10 g/dl or transfusion dependent) and had not
received previous erythropoietic therapy were
administered subcutaneous darbepoetin alfa at a
starting dose of 4.5 µg/kg/week.58 In preliminary
results, five of 10 evaluable patients showed a
major erythroid response (increase in
hemoglobin of > 2 g/dl in those whose
pretreatment level was < 11 g/dl, or transfusion
independence in those previously transfusion
dependent, according to the International
Working Group response criteria57).  These
patients received darbepoetin alfa 4.5
µg/kg/week, 9.0 µg/kg/week, or 9.0 µg/kg/week
plus granulocyte colony-stimulating factor 2.5
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Figure 4. Mean percentages (with 95% confidence
intervals) of patients with cancer-related anemia who
achieved a hematopoietic response during administration of
darbepoetin alfa every 3 or 4 weeks compared with those
who received placebo.  (From reference 53 with
permission.)
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µg/kg twice/week.  Darbepoetin alfa was
generally well tolerated.
In another small study, 12 patients with low-
and intermediate-risk myelodysplastic syndrome
and hemoglobin levels below 11 g/dl received
subcutaneous darbepoetin alfa for 6 months at a
starting dose of 150 µg/week.59 This weekly dose
was increased to 300 µg in nonresponders.
Overall, seven (58%) patients had a complete
response to treatment (hemoglobin concentration
increase of ≥ 2 g/dl or a level of 12 g/dl, with no
red blood cell transfusions).  In addition, a trend
seemed apparent toward reduction in apoptotic
cells associated with treatment response.  No
adverse effects associated with darbepoetin
treatment were observed.
Similar erythroid response rates using the
International Working Group criteria57 were
observed in another study involving patients with
low-risk myelodysplastic syndrome and anemia
(transfusion required or hemoglobin level < 10
g/dl).60 Patients received darbepoetin alfa 300
µg/week for at least 12 weeks.  Of 40 evaluable
patients, 24 (60%) responded at 12 weeks.
Nineteen patients experienced a major erythroid
response (hemoglobin increase of > 2 g/dl in
patients with pretreatment levels < 11 g/dl, or
transfusion independence in those previously
transfusion dependent), and five patients had a
minor erythroid response (hemoglobin increase
of 1–2 g/dl in patients with pretreatment levels of
< 11 g/dl, or 50% decrease in transfusion
requirements in those who were transfusion
dependent).  Two additional patients responded
after 12 additional weeks of treatment with
darbepoetin alfa plus granulocyte colony-
stimulating factor 100 µg 3 times/week.  No
adverse effects were observed.
Factors predicting a response to darbepoetin
alfa treatment were explored in a study involving
37 patients with anemia who had low-to-
intermediate risk myelodysplastic syndrome.61
After at least 12 weeks of treatment with
darbepoetin alfa 150 µg/week, 15 (41%) patients
achieved an erythroid response (13 major and 2
minor, according to the International Working
Group criteria57).  Multivariate analysis found
that a baseline serum level of endogenous
erythropoietin below 100 IU/L, limited or no
need for transfusions, no excess blasts, and
hypoplastic bone marrow significantly predicted
a response.
A retrospective chart review examining the
impact of switching treatments in patients with
myelodysplastic syndrome stabilized with
epoetin alfa to darbepoetin alfa 200 µg every 2
weeks found comparable clinical outcomes with
both treatments.62 Using the International
Working Group definitions,57 a major erythroid
response was observed in 27% (95% CI 15–39%)
of the 62 patients treated with darbepoetin alfa
and in 19% (95% CI 7–30%) of the 50 treated
with epoetin alfa.  A minor response was
observed in 46% (95% CI 33–59%) and 47%
(95% CI 31–63%) of the patients, respectively.  A
similar proportion of patients in both treatment
groups required a red blood cell transfusion, with
8% (95% CI 1–15%) and 12% (95%, CI 3–22%),
respectively.
A recent open-label clinical study explored the
use of darbepoetin alfa at extended dosing
intervals to treat anemia in patients with low- or
intermediate-1–risk myelodysplastic syndrome.63
In this study, myelodysplastic syndrome was
defined using the criteria of the International
Prognostic Scoring System64 and the French-
American-British Cooperative Group.65 Patients
with anemia (hemoglobin level ≤ 11 g/dl)
received darbepoetin alfa 500 µg every 3 weeks
for 13 weeks.  In an interim analysis based on
data for 100 patients, of 63 patients naïve to
erythropoietic therapy, 77% (95% CI 66–88%)
had an overall erythroid response (major plus
minor, defined according the International
Working Group criteria.57) and 47% (95% CI
34–60%) had a major response.  Of 37 patients
who had previously received erythropoietic
therapy, 36% (95% CI 20–53%) had an overall
erythroid response and 21% (95% CI 7–35%) had
a major response.  The proportion of patients
who had versus had not received previous
erythropoietic therapy who required a trans-
fusion during the study period was 32% (95% CI
17–48%) versus 17% (95% CI 8–27%).
Taken together, the results of these small
studies suggest that darbepoetin alfa is effective
in treating anemia in patients with myelodys-
plastic syndrome.  However, larger, randomized
studies are needed to confirm these findings and
to delineate the proper dosing schedule.
Safety Profile
In clinical studies involving patients with
cancer, adverse events reported for those
receiving darbepoetin alfa were comparable to
those reported for patients receiving placebo,44 or
were generally consistent with adverse events
expected in the populations studied.44, 53 Dosage
adjustment may be necessary to minimize the
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risk of rapid increases in hemoglobin concen-
trations or in achieving excessive concentrations.
A pooled analysis of data from five randomized
trials attempted to define what constitutes an
excessive rate of rise in hemoglobin concen-
tration.66 Results suggested that an increase of 2
g/dl in 28 days may be associated with an
increased risk of thrombotic events in patients
receiving darbepoetin alfa versus placebo.  However,
no significant differences in the exposure-adjusted
rate of embolism or thrombosis events were
observed between extended-interval (every 3
wks) and weekly administration.  Based on the
results of studies so far, darbepoetin alfa also
appears well tolerated in patients who have
myelodysplastic syndrome, with no or few treat-
ment-associated adverse effects observed.58–61, 63
Two trials involved patients with anemia who
had breast cancer67 and head and neck cancer68
who were treated with rHuEPO (epoetin alfa and
epoetin beta).  The reported data from these trials
have raised concerns regarding the safety of
erythropoietic treatment (particularly regarding
occurrence of thrombotic events) and its impact
on overall survival in patients with cancer.
However, the Oncology Drug Advisory
Committee of the FDA concluded that current
dosage recommendations for erythropoietic
therapy are adequate to minimize the risk of
thrombotic events, although further research into
its effect on overall and progression-free patient
survival is warranted.69
A meta-analysis of data from four randomized,
placebo-controlled trials involving patients with
chemotherapy-induced anemia indicated that
treatment with darbepoetin alfa is associated with
both a reduced risk of need for blood transfusions
and improved hematologic and hematopoietic
responses.70 In addition, the findings indicated
that a negative effect on survival is unlikely in
this patient population.
Conclusion
Early and adequate management of anemia in
patients with cancer or myelodysplastic
syndrome is important to help ameliorate adverse
effects of the anemia.  Evidence indicates that
darbepoetin alfa and epoetin alfa are equally
effective in treating anemia in these patient
populations.  However, data from clinical trials,
drug use evaluations, and retrospective cohort
studies suggest that darbepoetin alfa has the
potential to improve the management of
chemotherapy- and cancer-related anemia
through a more flexible dosing schedule compared
with epoetin alfa.  Studies are under way to
determine whether epoetin alfa can be administered
effectively at extended intervals.
The studies reviewed in this article confirm
that darbepoetin alfa administered at extended
dosing intervals (every 2, 3, or 4 wks) corrects
and maintains hemoglobin concentrations in
patients with chemotherapy- and cancer-related
anemia, and that early intervention in patients
with mild anemia has clinical benefits.  The
extended dosing intervals possible with
darbepoetin alfa are expected to decrease the
burden on patients and their caregivers regarding
the number of clinic visits required for anemia
management.  Less frequent administration also
could reduce the time clinicians spend preparing
and administering anemia treatment.  Time-and-
motion data confirm that reducing the number of
clinic visits required to treat cancer-associated
anemia and neutropenia by using long-acting
growth factors results in significant time savings
for clinic staff.  Many chemotherapy regimens are
administered in a 3-week cycle.  Thus,
administering darbepoetin alfa every 3 weeks
may also represent an opportunity for health care
providers to synchronize anemia treatment in
patients receiving chemotherapy by permitting
darbepoetin alfa administration once/cycle.
Although the original FDA-approved dosage of
darbepoetin alfa for patients with chemotherapy-
induced anemia is 2.25 µg/kg/week, the
minimum effective weekly dose has been identified
as 1.5 µg/kg/week.  As the studies described have
shown, the equivalent dosages of 3.0 µg/kg every
2 weeks and 4.5 µg/kg every 3 weeks are equally
effective in this population.  The FDA has
approved only one fixed-dose regimen:
darbepoetin alfa 500 µg every 3 weeks.  However,
74% of patients starting treatment at this dose
needed a dose reduction.
Further investigations showed similar results
with fixed darbepoetin alfa doses of approxi-
mately 100 µg/week, 200 µg every 2 weeks, and
300 µg every 3 weeks.  Therefore, trials
comparing fixed darbepoetin alfa doses of 300 µg
and 500 µg every 3 weeks are planned.  No data
are available yet regarding a fixed dose for
patients with chronic anemia of cancer.
However, these findings suggest that in the
future, management of anemia in patients with
cancer may be further simplified by the
introduction of fixed dosing for darbepoetin alfa.
Data from both prospective and retrospective
studies suggest that darbepoetin alfa is effective
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in maintaining hemoglobin concentrations in
patients with myelodysplastic syndrome who
were previously stabilized with other
erythropoietic therapies.  Trials have also shown
encouraging initial results in treating de novo
patients with myelodysplastic syndrome with
darbepoetin alfa.  In these trials, a substantial
proportion of patients showed correction of
hemoglobin concentrations or an erythroid
response (as defined by the International
Working Group criteria).  Although darbepoetin
alfa is not licensed for administration in patients
with myelodysplastic syndrome, its potential for
this indication is being explored in continuing
trials.
Darbepoetin alfa offers an attractive therapy
option for patients with chemotherapy- or
cancer-induced anemia.  It has the potential of
increased flexibility and simple administration,
and it may offer an effective treatment for anemia
in patients with myelodysplastic syndrome.
Addendum
On January 26, 2007, after submission of this
manuscript but before publication, Amgen Inc.
(Thousand Oaks, CA), the manufacturer of
darbepoetin alfa, posted a safety alert on the
FDA’s Web site (www.fda.gov) regarding the use
of darbepoetin in patients with cancer who are
not receiving concurrent chemotherapy.  A large,
phase III, multicenter, randomized, placebo-
controlled study, sponsored by Amgen (not
published at the time of publication of this
article), showed that darbepoetin was ineffective
in reducing red blood cell transfusions in patients
with cancer who have anemia that is not due to
concurrent chemotherapy. In addition, this study
found a higher mortality rate in patients
receiving darbepoetin.  The study compared
darbepoetin with placebo in patients with active
malignant disease who were not receiving or
expected to receive chemotherapy or radiation
therapy.  The study failed to meet its primary end
point of reducing red blood cell transfusions in
the darbepoetin group.  In addition, more deaths
occurred in the darbepoetin treatment group
compared with the placebo group.
The study treatment period was 16 weeks, with
an additional 16-week extension study
comparing the safety and efficacy of darbepoetin
versus placebo.  The target hemoglobin level in
the darbepoetin group was 12 g/dl.  A total of 989
patients with hemoglobin levels below 11 g/dl,
who had active cancer, and who were not
receiving myelosuppressive chemotherapy or
radiotherapy, were enrolled.  Approximately 60%
of the patients enrolled had advanced (stage IV)
disease.  Analysis of the initial 16-week treatment
period did not show a statistically significant
effect on the primary efficacy end point (hazard
ratio 0.89, 95% CI 0.65–1.22), with a frequency
of red blood cell transfusions of 24% in the
placebo group versus 18% in the darbepoetin
group (p=0.15).  In addition, more deaths were
reported in the darbepoetin group (136/515
patients [26%]) than in the placebo group
(94/470 [20%]).  With median survival follow-up
of 4.3 months, the absolute number of deaths
was greater in the darbepoetin group compared
with those in the placebo group (250/515
patients [49%] vs 216/470 patients [46%]; hazard
ratio 1.25, 95% CI 1.04–1.51).
Although the studies referenced in our article
found that darbepoetin treatment improves
hemoglobin levels in patients with anemia of
cancer who are not receiving concomitant
chemotherapy, this new study raises concern
about the potential role of darbepoetin in this
population.
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